Colin Hill Presents at Gold Lab Symposium
On May 17, 2024, Colin Hill, CEO of Aitia, discussed the topic of “Digital Twins and the Discovery of New Drugs for Rare Diseases,” at the Gold Lab Forum. For more information, visit the event website.
BioCentury highlights GNS-Alexion partnership
Alexion rebuilding pipeline with big data deals August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4 (New York, N.Y.) for genomic sequencing and licensed the Reverse Engineering and Forward Simulation (REFS) […]
FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases
Alexion inks genomics pacts to continue R&D reboot August 11, 2017 – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics. Read the full article here. […]
Rare Disease Report Covers Alexion-GNS REFS Licensing Agreement
Rare Disease Treatments to Be Discovered by Machine Learning and Simulation Platform August 10, 2017 – Earlier today, Alexion Pharmaceuticals was granted the licensing rights to operate GNS Healthcare’s Reverse Engineering and Forward Simulation (REFS) casual machine learning and simulation platform. Alexion intends to use the platform to accelerate both the research of rare diseases […]
GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases
CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced that it has entered into a license arrangement with Alexion for the rights to operate its REFS™ […]